Verici Dx (Verici Dx) Days Payable : 60,650.83 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Days Payable?

Verici Dx's average Accounts Payable for the six months ended in Jun. 2023 was $1.00 Mil. Verici Dx's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.00 Mil. Hence, Verici Dx's Days Payable for the six months ended in Jun. 2023 was 60,650.83.

The historical rank and industry rank for Verici Dx's Days Payable or its related term are showing as below:

VRCDF' s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 116800
Current: 116800

During the past 3 years, Verici Dx's highest Days Payable was 116800.00. The lowest was 0.00. And the median was 0.00.

VRCDF's Days Payable is ranked better than
99.52% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: 68.79 vs VRCDF: 116800.00

Verici Dx's Days Payable increased from Jun. 2022 (0.00) to Jun. 2023 (60,650.83). It may suggest that Verici Dx delayed paying its suppliers.

Verici Dx Days Payable Historical Data

The historical data trend for Verici Dx's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Days Payable Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Days Payable

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	-	-	-	-	60,650.83

Competitive Comparison of Verici Dx's Days Payable

For the Diagnostics & Research subindustry, Verici Dx's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verici Dx's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Days Payable distribution charts can be found below:

* The bar in red indicates where Verici Dx's Days Payable falls into.

Verici Dx Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Verici Dx's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0.16	+	0.96)	/	2 )	/	0	*	365
=	0.56					/	0	*	365
=	N/A

Verici Dx's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (0.96	+	1.034)	/	2 )	/	0.003	*	365 / 2
=	0.997					/	0.003	*	365 / 2
=	60,650.83

Verici Dx Days Payable Related Terms

Thank you for viewing the detailed overview of Verici Dx's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines